China AI: Bernstein sees chipmakers benefiting from Nvidia scrutiny
Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), a $7.09 billion market cap biotechnology company, recently executed a stock transaction involving the sale of 3,058 shares of the company’s common stock. The shares were sold at an average price of $39.04 each, totaling approximately $119,385. According to InvestingPro analysis, the company’s current trading price of $38.75 appears fairly valued.
This transaction was carried out as part of a Rule 10b5-1 instruction letter, which was adopted on May 31, 2023, to satisfy Horn’s tax withholding obligations related to the vesting of restricted stock units (RSUs) after July 15, 2023. Following the sale, Horn retains ownership of 153,533 shares, including 89,050 RSUs. InvestingPro data shows the company maintains strong liquidity with a current ratio of 14.2 and holds more cash than debt on its balance sheet. Analysts have set price targets ranging from $59 to $87, suggesting potential upside. Get access to the full Revolution Medicines research report and 7 additional ProTips with an InvestingPro subscription.
In other recent news, Revolution Medicines reported a net loss of $1.12 per share for the fourth quarter, which was larger than the expected loss of $0.94 per share. The company attributed this discrepancy to higher than anticipated operating expenses, particularly in research and development. Despite the increased losses, Revolution Medicines ended 2024 with a strong cash position of $2.3 billion, supported by an $823 million equity offering. Analysts at H.C. Wainwright raised their price target for Revolution to $73, maintaining a Buy rating due to the company’s robust balance sheet and potential future data catalysts. Conversely, Needham adjusted its price target down to $59, also maintaining a Buy rating, reflecting the higher projected expenses for 2025.
Revolution Medicines announced plans for two additional registrational trials for its drug daraxonrasib, focusing on pancreatic ductal adenocarcinoma (PDAC). These trials are expected to start in the second half of 2025. Analysts at Needham anticipate a positive market response to this expansion, particularly in the adjuvant setting, as it could broaden the drug’s addressable market. Investors are advised to watch for upcoming clinical data on zoldonrasib as both a monotherapy and in combination therapy, expected in 2025. These recent developments highlight Revolution Medicines’ strategic focus on advancing its clinical-stage RAS inhibitors and expanding its treatment options for RAS-addicted cancers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.